Schrödinger, Inc. (SDGR) Stock Analysis
Healthcare · Health Information Services · NasdaqGS
Schrödinger, Inc. (SDGR) posted $255.87M in revenue for fiscal 2025 (up 23.3% year over year), with a net loss of $103.27M, and has compounded revenue about 18.8%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Schrödinger, Inc.
Schrödinger, Inc. has grown revenue from $85.54M to $255.87M over the last 7 fiscal years, compounding about 18.8% a year. The most recent year was up 23.3%, so growth is actually accelerating.
Net margin sits at -40.4%, up 49.8 points year over year on a 55.7% gross margin.
At today's valuation the market is pricing in roughly 27.5% annual free-cash-flow growth — versus the -2.6% it actually delivered over the last five years, so the price already assumes a step-up from the recent record. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Schrödinger, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Schrödinger, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $85.54M | $108.09M | $137.93M | $181.00M | $216.70M | $207.54M | $255.87M |
| Gross profit | $49.09M | $63.47M | $65.62M | $101.02M | $140.69M | $132.08M | $142.61M |
| Net income | $-24.57M | $-24.46M | $-100.39M | $-149.20M | $40.72M | $-187.12M | $-103.27M |
| Net margin | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
Source: Schrödinger, Inc. SEC filings (10-K).
Schrödinger, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -40.4%).
What growth is priced into SDGR stock?
At today's market cap of $1.05B, Schrödinger, Inc. is priced for free-cash-flow growth of about 27.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.46M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -2.6%/yr over the last five fiscal years and revenue 18.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Schrödinger, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SDGR in your portfolio →
Schrödinger, Inc. financial history by metric
Compare Schrödinger, Inc. with peers
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc. — frequently asked questions
What is Schrödinger, Inc.'s revenue?
Schrödinger, Inc. (SDGR) reported revenue of $255.87M for fiscal year 2025, up 23.3% from the prior year, according to its SEC filings.
Is Schrödinger, Inc. profitable?
No — SDGR reported a net loss of $-103.27M in fiscal 2025.
What is SDGR's P/E ratio?
Schrödinger, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Schrödinger, Inc. growing?
SDGR's revenue grew at roughly 18.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Schrödinger, Inc. have?
As of fiscal year 2025, SDGR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Schrödinger, Inc.'s gross margin?
SDGR's gross margin was 55.7% in fiscal 2025 — gross profit of $142.61M on revenue of $255.87M.
What is Schrödinger, Inc.'s market cap?
Schrödinger, Inc. (SDGR) has a market capitalization of about $1.05B, based on the latest data in our nightly-refreshed cache.
When does Schrödinger, Inc.'s fiscal year end?
SDGR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SDGR stock?
At today's market cap of $1.05B, Schrödinger, Inc. is priced for free-cash-flow growth of about 27.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.46M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -2.6%/yr over the last five fiscal years and revenue 18.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Schrödinger, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.